Sonazoid™
Phase 1Small molecule
Sonazoid™ is one of 153 small molecule programs targeting Hyperplasia. It is currently in Phase 1.
4
Indications
10
Total Trials
1
Active Trials
152
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
341 competitors in Esophageal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Paraplatin
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Erbitux
IImclone
Phase 3
Ellence
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Stivarga
BayerPhase 3
Lovenox
SanofiPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ultrasound2 trials
Efficacy and Safety1 trial
Renal Transplant Rejection1 trial
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
Completed·—·Phase 2·NCT02733029·8 enrolled
4 more indications
Esophageal Cancer1 trial
Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT03578224·35 enrolled
Liver1 trial
Intravenous1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sonazoid™. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGE Healthcare